Lexaria Bioscience Corp. (LEXX) earnings date, results and what the price requires
Nasdaq · SEC CIK 0001348362 · SEC filings checked Oct 17, 2026
Next report
Oct 12, 2026
Estimated from reporting history (91-day cycle, SEC periodic report filing dates). Not confirmed.
Last close
$2.86
Polygon.io daily close, Oct 16, 2026. End of day, not live.
Trailing diluted EPS
$-0.35
Sum of quarters ending May 31, 2026, Feb 28, 2026, Nov 30, 2025, Aug 31, 2025
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| May 31, 2026 | Jul 13, 2026 | $0 | $-2.0M | $-0.08 | Filing |
| Feb 28, 2026 | Apr 13, 2026 | $20,000 | $-1.4M | $-0.06 | Filing |
| Nov 30, 2025 | Jan 13, 2026 | $0 | $-1.6M | $-0.07 | Filing |
| Aug 31, 2025 | Nov 28, 2025 | $174,000 | $-2.7M | $-0.14 | Filing |
| May 31, 2025 | Jul 14, 2025 | $174,000 | $-3.8M | $-0.21 | Filing |
| Feb 28, 2025 | Apr 14, 2025 | $174,000 | $-2.7M | $-0.15 | Filing |
| Nov 30, 2024 | Jan 10, 2025 | $183,923 | $-2.7M | $-0.16 | Filing |
| Aug 31, 2024 | Nov 26, 2024 | $84,000 | $-2.2M | $-0.15 | Filing |
What would Lexaria Bioscience Corp. have to report for its valuation to change?
Trailing earnings are negative, so a price-to-earnings reverse model does not apply. The model is not shown rather than filled with assumptions.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.